<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00601094</url>
  </required_header>
  <id_info>
    <org_study_id>03-06-008</org_study_id>
    <secondary_id>UCLA-NCI-7888</secondary_id>
    <secondary_id>10-000039</secondary_id>
    <nct_id>NCT00601094</nct_id>
  </id_info>
  <brief_title>Vaccine Therapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Phase I Trial of CCL21 Gene Modified Dendritic Cells In Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines made from a gene-modified virus may help the body build an effective&#xD;
      immune response to kill tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in&#xD;
      treating patients with stage IIIB, stage IV, or recurrent non-small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To determine the safety, toxicity, and maximum tolerated dose (MTD) of autologous&#xD;
           dendritic cell-adenovirus CCL21 vaccine administered as an intratumoral injection in&#xD;
           treating patients with stage IIIB, IV, or recurrent non-small cell lung cancer.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To determine the biologic and clinical responses to therapy.&#xD;
&#xD;
        -  To determine treatment-related toxicity using the NCI Common Toxicity Criteria.&#xD;
&#xD;
        -  To identify the MTD.&#xD;
&#xD;
        -  To monitor patients for evidence of autologous dendritic cell-adenovirus CCL21&#xD;
           vaccine-induced cytokines and antigen-specific immune responses.&#xD;
&#xD;
        -  To detect immune responses to tumor-associated antigens and vector.&#xD;
&#xD;
        -  To assess patients for objective signs of tumor regression (RECIST Criteria).&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of autologous dendritic cell-adenovirus CCL21&#xD;
      vaccine.&#xD;
&#xD;
      Patients undergo leukapheresis to obtain leukocytes for generation of autologous dendritic&#xD;
      cells (DC). Adenovirus carrying the CCL21 gene is added to the dendritic cells to make the&#xD;
      vaccine. Approximately 2 weeks after leukapheresis, patients receive an intratumoral&#xD;
      injection of autologous dendritic cell-adenovirus CCL21 vaccine under CT-guidance or by&#xD;
      bronchoscopy on days 0 and 7. Patients demonstrating a clinical response are eligible to&#xD;
      receive a second round of gene transfer at their discretion and in consultation with the FDA.&#xD;
&#xD;
      Cohorts of 3 patients receive escalating doses of autologous dendritic cell-adenovirus CCL21&#xD;
      vaccine until the maximum tolerated dose (MTD) is determined. An additional 12 patients are&#xD;
      treated at the MTD.&#xD;
&#xD;
      Patients undergo blood sample collection at baseline and then on days 0, 7, 14, 28, and 56&#xD;
      for safety and immunological studies. Blood samples are analyzed for mycoplasma by PCR;&#xD;
      dendritic cell phenotype by flow cytometry; detection of adenovirus CCL21 by nested PCR; and&#xD;
      adenoviral antibodies by ELISA. Patients also undergo tissue aspirate or biopsy on days 0 and&#xD;
      7 (during bronchoscopy or CT-guided procedure). Tissue samples are analyzed for&#xD;
      immune-modulating cytokines (i.e., IFNγ, CXCL9, and CXCL10) by quantitative RT-PCR; detection&#xD;
      of tumor infiltrating leukocytes by immunohistochemistry; CD83+ DC, CXCR3, CCR7, CCL21 and&#xD;
      CD3+ T-cells, CD4, and CD8 by flow cytometry; determination of tumor expression of&#xD;
      tumor-associated antigen by RT-PCR; and evaluation of immune modulation by ELISPOT assays.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 26, 2009</start_date>
  <completion_date type="Actual">May 23, 2017</completion_date>
  <primary_completion_date type="Actual">May 23, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity as measured by NCI Common Toxicity Criteria</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease status at days 28 and 56</measure>
    <time_frame>56 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune response assessment by antigen-specific IFNγ ELISPOT assays on days 0, 28, and 56</measure>
    <time_frame>56 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>experimental arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>autologous dendritic cell-adenovirus CCL21 vaccine</intervention_name>
    <description>Eligible patients will be assigned to a cohort and will receive intratumoral injections of Ad-CCL21-DC in conjunction with tumor sampling.</description>
    <arm_group_label>experimental arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults over the age of 21 capable of giving informed consent&#xD;
&#xD;
          -  Pathologically confirmed non-small cell lung cancer (NSCLC)&#xD;
&#xD;
          -  Stage IIIB, IV, or recurrent disease&#xD;
&#xD;
          -  Progressive disease despite one or more prior chemotherapy regimens as standard of&#xD;
             care OR patient refuses standard chemotherapy&#xD;
&#xD;
          -  Measurable metastatic disease by RECIST guidelines&#xD;
&#xD;
          -  Patients with a major endobronchial lesion in the segmental, lobar, or mainstem&#xD;
             bronchus with complete obstruction of the airway may be eligible for bronchoscopic&#xD;
             injection provided there is no evidence of respiratory failure (defined as SaO_2 &gt; 90%&#xD;
             on room air, PCO_2 &lt; 45 mm Hg, or FEV_1 &gt; 1.0 L)&#xD;
&#xD;
          -  Patients with an endobronchial lesion in the segmental bronchus with variable stenosis&#xD;
             (not completely obstructed) and not amenable to standard palliative airway treatments&#xD;
             (i.e., laser and stenting) may be eligible for bronchoscopic injection if there is no&#xD;
             evidence of respiratory failure (defined as SaO_2 &gt; 90% on room air, PCO_2 &lt; 45 mm Hg,&#xD;
             or FEV_1 &gt; 1.0 liters)&#xD;
&#xD;
          -  Patients with bullous disease may undergo CT-guided transthoracic injection provided&#xD;
             the targeted tumor has an intended needle path without crossing bullae&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  BUN ≤ 40 OR serum creatinine ≤ 2&#xD;
&#xD;
          -  Serum total bilirubin ≤ 1.5 OR serum transaminases ≤ 2.5 times upper limit of normal&#xD;
             (ULN)&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  More than 14 days since prior acute therapy for viral, bacterial, or fungal infections&#xD;
&#xD;
          -  More than 30 days since prior and no concurrent corticosteroids&#xD;
&#xD;
          -  More than 30 days since prior radiotherapy, chemotherapy, or noncytotoxic&#xD;
             investigational agents&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  active CNS metastasis (i.e., progression of CNS disease during the past 30 days&#xD;
             without intervention)&#xD;
&#xD;
          -  evidence of coagulopathy, defined as PT and/or PTT ≤ 1.5 times ULN OR platelets ≥&#xD;
             100,000/mm^3&#xD;
&#xD;
          -  evidence of leukoplakia, defined as absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  evidence of respiratory failure (defined as SaO_2 &gt; 90% on room air, PCO_2 &lt; 45 mm Hg,&#xD;
             or FEV_1 &gt; 1.0 L)&#xD;
&#xD;
          -  NYHA class III-IV cardiac disease within the past year&#xD;
&#xD;
          -  myocardial infarction within the past year&#xD;
&#xD;
          -  comorbid disease or medical condition that would impair the ability of the patient to&#xD;
             receive or comply with the study protocol&#xD;
&#xD;
          -  acute viral, bacterial, or fungal infection that requires specific therapy&#xD;
&#xD;
          -  HIV positivity&#xD;
&#xD;
          -  hypersensitivity to any reagents used in the study&#xD;
&#xD;
          -  signs or symptoms of acute adenoviral infection (i.e., conjunctivitis or documented&#xD;
             adenoviral upper respiratory infection)&#xD;
&#xD;
          -  prior or concurrent evidence of autoimmune disease&#xD;
&#xD;
          -  pregnant or nursing&#xD;
&#xD;
          -  prior organ allograft&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jay M. Lee, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Greater Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>January 10, 2008</study_first_submitted>
  <study_first_submitted_qc>January 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2008</study_first_posted>
  <last_update_submitted>July 30, 2020</last_update_submitted>
  <last_update_submitted_qc>July 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

